Literature DB >> 15574771

Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities.

Ivan Topisirovic1, Melisa Ruiz-Gutierrez, Katherine L B Borden.   

Abstract

The eukaryotic translation initiation factor eIF4E is dysregulated in a wide variety of human cancers. In the cytoplasm, eIF4E acts in the rate-limiting step of translation initiation whereas in the nucleus, eIF4E forms nuclear bodies and promotes the nucleo-cytoplasmic export of a subset of growth-promoting mRNAs including cyclin D1. The only known post-translational modification of eIF4E is its phosphorylation at S209. Many studies have examined the role of phosphorylation on cap-dependent translation. However, no studies to date have explored the role of phosphorylation on the ability of eIF4E to transform cells. Using mutagenesis and separately a small molecular inhibitor of eIF4E phosphorylation, we show that eIF4E phosphorylation enhances both its mRNA transport function and its transformation activity in cell culture. Thus, phosphorylation of nuclear eIF4E seems to be an important step in control of the mRNA transport and thus the transforming properties of eIF4E.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15574771     DOI: 10.1158/0008-5472.CAN-04-2677

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  111 in total

1.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

2.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.

Authors:  Luc Furic; Liwei Rong; Ola Larsson; Ismaël Hervé Koumakpayi; Kaori Yoshida; Andrea Brueschke; Emmanuel Petroulakis; Nathaniel Robichaud; Michael Pollak; Louis A Gaboury; Pier Paolo Pandolfi; Fred Saad; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

3.  Human herpesvirus-encoded kinase induces B cell lymphomas in vivo.

Authors:  Penny M Anders; Nathan D Montgomery; Stephanie A Montgomery; Aadra P Bhatt; Dirk P Dittmer; Blossom Damania
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

4.  Roles of mitogen-activated protein kinase signal-integrating kinases 1 and 2 in oxidant-mediated eIF4E phosphorylation.

Authors:  Jeffrey S Shenberger; Lianqin Zhang; Mariah K Hughlock; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga
Journal:  Int J Biochem Cell Biol       Date:  2007-05-10       Impact factor: 5.085

Review 5.  Translational Control in Cancer.

Authors:  Nathaniel Robichaud; Nahum Sonenberg; Davide Ruggero; Robert J Schneider
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-07-01       Impact factor: 10.005

6.  High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma.

Authors:  Chi-Ju Yeh; Wen-Yu Chuang; Yin-Kai Chao; Yun-Hen Liu; Yu-Sun Chang; Shao-Yun Kuo; Chen-Kan Tseng; Hsien-Kun Chang; Chuen Hsueh
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

Review 7.  Serine-threonine protein phosphatases: Lost in translation.

Authors:  Victoria Kolupaeva
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-08-20       Impact factor: 4.739

Review 8.  Regulation of translation initiation in eukaryotes: mechanisms and biological targets.

Authors:  Nahum Sonenberg; Alan G Hinnebusch
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

9.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

10.  Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Fernanda Musa; Amandine Alard; Gizelka David-West; John P Curtin; Stephanie V Blank; Robert J Schneider
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.